Navigation Links
Tremor in Medical Technology

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

... weight increase (5% in monotherapy trial) and tremor and parkinsonism (greater than or equal to 10% in ... (4%, 11%, 6%), Parkinsonism+ (8%, 15%, 9%) and tremor (0%, 3%, 0%). * Akathisia and restlessness ... weight increase (5% in monotherapy trial) and tremor and parkinsonism (greater than or equal to 10% in ...

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

... stage of the Altropane Parkinson's or Essential tremor (POET-2) Phase III clinical program. The ... 11 million people in the U.S. alone living with tremor disorders of which more than one million have ... high as 35-50%. "Millions of people experiencing tremor symptoms currently have no objective means to ...

Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program

... of the ALTROPANE(R) Parkinson's or Essential tremor - 2 (POET-2) Phase III clinical trial program. ... are presently living with tremor. Currently, tremor disorders are diagnosed by subjective clinical ... to help doctors more accurately diagnose tremor to minimize the side-effects of unnecessary ...

Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program

... sites for the first stage of the ALTROPANE(R) Parkinson's or Essential tremor - 2 (POET-2) Phase III clinical trial program are now open for ... imaging process which benefits both the patient and the clinic." The tremor Action Network estimates that as many as 10 million people in the United ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... of schizophrenia were reactions at the injection site, sleepiness, dizziness, feeling of inner restlessness, and abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of the eyes. This is not a complete list of all possible ...

WORLD'S First Robotic Assisted Kidney Transplant Performed at Saint Barnabas Medical Center

... through several small incisions. Pencil-sized probes translate the surgeon's hand movements and adjust themselves to compensate for the natural tremor of the human hand. For the patient, robot-assisted surgery is safe, minimally invasive and offers faster recovery time. Although the recovery ...

Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline)

... * Parkinson's disease is a progressive neurodegenerative disorder which is characterized by motor symptoms such as slowness of movement, rigidity, tremor and postural instability. The symptoms of this disease result from the progressive degeneration of certain nerve cells located in a specific area in ...

U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease

... a key chemical in the brain that communicates messages about movement, resulting in the symptoms of Parkinson's disease. These symptoms include tremor (involuntary shaking), rigidity (stiffness), akinesia (lack of movement or loss of spontaneous movement), bradykinesia (slower-than-normal voluntary ...

Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain

... group, which were greater than placebo, were dizziness (16.3 vs. 5.2 percent), nausea (10.3 vs. 6.2 percent), fatigue (6.7 vs. 4.1 percent) and tremor (6.5 vs. 1.0 percent). In addition, lacosamide had no effect on body weight in these trials. About lacosamide Lacosamide has a dual mode of ...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)

... vs placebo, respectively): -- Adult patients with bipolar mania: constipation (13% vs 6%), akathisia (15% vs 3%), sedation (8% vs 3%), tremor (7% vs 3%), restlessness (6% vs 3%), and extrapyramidal disorder (5% vs 2%) -- Pediatric patients (10 to 17 years) with Bipolar I Disorder: ...

INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients

... of 10% were headache (INVEGA 14%, SEROQUEL 12% and placebo 16%), hypertonia (12%, 4%, 4%), sedation (4%, 11%, 4%), somnolence (11%, 15%, 3%), tremor (20%, 8%, 15%), dizziness (4%, 15%, 1%), schizophrenia (6%, 9%, 13%) and insomnia (12%, 10%, 15%). During the study, 8 percent of the INVEGA ...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

... for Parkinson's patients. When symptoms like slowness of movement, tremor and rigidity return due to wearing off of the patient's medication, it can ... (slower-than- normal voluntary movements), rigidity (stiffness), tremor (involuntary shaking) and postural instability (trouble with balance). ...

Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants

... (15% vs 3%), constipation (13% vs 6%), sedation (8% vs 3%), tremor (7% vs 3%), restlessness (6% vs 3%), and extrapyramidal disorder ... a 26-week trial in schizophrenia except for a higher incidence of tremor (aripiprazole 8% vs placebo 2%). Aripiprazole Injection ...

Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

... (15% vs 3%), constipation (13% vs 6%), sedation (8% vs 3%), tremor (7% vs 3%), restlessness (6% vs 3%), and extrapyramidal disorder (5% ... in a 26-week trial in schizophrenia except for a higher incidence of tremor (aripiprazole 8% vs placebo 2%). Aripiprazole Injection ...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

... 25%), pyrexia (23% vs 19%), nausea (22% vs 19%), headache (21% vs 21%), peripheral edema (21% vs 19%), dizziness (21% vs 15%), dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and ...

Early Results of the CellCept Spare the Nephron Study Examine Kidney Function

... BUN and cough increased, hypomagnesemia, diarrhea, constipation, nausea, vomiting, respiratory infection, dyspnea, lung disorder, pleural effusion, tremor and insomnia. Patients receiving immunosuppressant regimens are at increased risk of developing lymphomas and other malignancies, particularly of ...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

... in this study were consistent with the SNRI class and included nausea, dry mouth, insomnia, somnolence, sweating, anorexia (loss of appetite), tremor and impotence. About Desvenlafaxine Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) studied as a potential treatment for ...
Other Contents
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... State University,s College of Engineering recently received a ... the project, "Nanoparticle-directed synthesis of organic nanorods." ... is the creation and utilization of functional materials, ... A major bottleneck in scaling up nanotechnology is ... functional materials into one device. A research team ...
(Date:7/30/2014)... Embryonic stem cells can develop into a multitude of cells ... development into the specific types of mature cells that make ... , One key seems to be long chains of sugars ... Godula,s group at the University of California, San Diego, has ... sugars, but can be more easily manipulated to direct the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
(Date:7/30/2014)... Imprivata ® (NYSE: IMPR), ... secure communications solutions for the healthcare industry, today ... most widely selected single sign-on (SSO) solution amongst ... medical records (EMR) systems with a 51 percent ... in the last 12 months), according to HIMSS ...
(Date:7/30/2014)... obese people have a genetic mutation that seems to ... they see food, researchers report. Gaining a better ... and gratification at the sight of high-calorie foods like ... the scientists suggested. More than one-third of U.S. ... a combination of overeating, a lack of physical activity ...
(Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... As the controversy surrounding the use ... continues to grow, Bernstein Liebhard LLP notes that another ... a ban on uterine morcellation. According to a report ... leiomyosarcoma following a hysterectomy that involved the use of ... the aggressive cancer had progressed to Stage 4. Ms. ...
Breaking Medicine News(10 mins):Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Gene Mutation May Make Food More Tempting 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
Other TagsOther Tags